The clinical trial plan by a research team led by Professor Hiroshi Kawamoto of Kyoto
University, a founder of Rebirthel, was featured in the Nikkei Shimbun on November 30,
2025. The trial is scheduled to begin in 2027 and will evaluate a novel immunotherapy for
acute myeloid leukemia (AML) that uses universal killer T cells derived from iPS cells.
This technology has been transferred to Rebirthel, and the company will take over the
outcomes of the clinical trial conducted at Kyoto University.
A key feature of this therapy is its off-the-shelf design. Killer T cells can be produced in
advance from donor-derived iPS cells, expanded, and cryopreserved, removing the need to
search for a hematopoietic stem cell donor. This approach may help address treatment
delays associated with conventional hematopoietic stem cell transplantation and provide
faster access to therapy for more patients.
Rebirthel will continue to advance research and business development toward a future in
which cell therapy is a standard treatment option for all patients.
Link to the article (Available to members and only in Japanese)